These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 4049626

  • 1. Overview of treatment of superficial bladder cancer.
    Soloway MS.
    Urology; 1985 Oct; 26(4 Suppl):18-26. PubMed ID: 4049626
    [Abstract] [Full Text] [Related]

  • 2. Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma.
    Soloway MS, Jordan AM, Murphy WM.
    Prog Clin Biol Res; 1989 Oct; 310():215-36. PubMed ID: 2505268
    [Abstract] [Full Text] [Related]

  • 3. Intravesical therapy for bladder cancer.
    Soloway MS.
    Urol Clin North Am; 1988 Nov; 15(4):661-9. PubMed ID: 3142129
    [Abstract] [Full Text] [Related]

  • 4. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
    Gofrit ON, Shapiro A, Pode D, Sidi A, Nativ O, Leib Z, Witjes JA, van der Heijden AG, Naspro R, Colombo R.
    Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
    [Abstract] [Full Text] [Related]

  • 5. [Management of Ta, T1, and in situ bladder carcinoma: what is new?].
    Irani J.
    Prog Urol; 2008 May; 18 Suppl 5():S94-8. PubMed ID: 18585634
    [Abstract] [Full Text] [Related]

  • 6. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
    Herr HW.
    J Urol; 2005 Dec; 174(6):2134-7. PubMed ID: 16280743
    [Abstract] [Full Text] [Related]

  • 7. Introduction and overview of intravesical therapy for superficial bladder cancer.
    Soloway MS.
    Urology; 1988 Mar; 31(3 Suppl):5-16. PubMed ID: 3126593
    [Abstract] [Full Text] [Related]

  • 8. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP, Witjes JA, Oosterhof GO, Debruyne MJ.
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [Abstract] [Full Text] [Related]

  • 9. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED.
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [Abstract] [Full Text] [Related]

  • 10. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
    Lebret T, Bohin D, Kassardjian Z, Herve JM, Molinie V, Barre P, Lugagne PM, Botto H.
    J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
    [Abstract] [Full Text] [Related]

  • 11. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
    Yumura Y, Oogo Y, Takase K, Hamano A, Yamashita Y, Noguchi S, Satomi Y.
    Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
    [Abstract] [Full Text] [Related]

  • 12. Should all superficial bladder tumors be treated with intravesical therapy?
    Soloway MS.
    Prog Clin Biol Res; 1989 Nov; 303():491-501. PubMed ID: 2675006
    [Abstract] [Full Text] [Related]

  • 13. Use of mitomycin as prophylaxis following endoscopic resection of superficial bladder cancer.
    Huland H, Otto U.
    Urology; 1985 Oct; 26(4 Suppl):32-5. PubMed ID: 4049627
    [Abstract] [Full Text] [Related]

  • 14. Mitomycin for patients who have failed on thiotepa. The National Bladder Cancer Group.
    Koontz WW, Heney NM, Soloway MS, Kluskens L, Hazra TA, Trump DL, Barton B.
    Urology; 1985 Oct; 26(4 Suppl):30-1. PubMed ID: 3931326
    [Abstract] [Full Text] [Related]

  • 15. [Studies on multiple mucosal biopsy in patients with bladder cancer. 2. Evaluation on the relationship between the results of multiple mucosal biopsy and recurrence, and the clinical course of cases with carcinoma in situ and micro-invasion of carcinoma in situ].
    Igawa M.
    Hinyokika Kiyo; 1986 Nov; 32(11):1633-47. PubMed ID: 3825813
    [Abstract] [Full Text] [Related]

  • 16. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
    Huguet J, Crego M, Sabaté S, Salvador J, Palou J, Villavicencio H.
    Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Managing superficial bladder cancer: an overview.
    Soloway MS.
    Urology; 1992 Dec; 40(6 Suppl):5-10. PubMed ID: 1466119
    [Abstract] [Full Text] [Related]

  • 19. Superficial bladder cancer: part 1. Update on etiology, classification and natural history.
    Josephson DY, Pasin E, Stein JP.
    Expert Rev Anticancer Ther; 2006 Dec; 6(12):1723-34. PubMed ID: 17181486
    [Abstract] [Full Text] [Related]

  • 20. Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation.
    Takayama H, Nishimura K, Tsujimura A, Nakai Y, Nakayama M, Aozasa K, Okuyama A, Nonomura N.
    J Urol; 2009 Apr; 181(4):1894-900. PubMed ID: 19237175
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.